AtaiBeckley BPL-003 Phase 2b Data Secures FDA Breakthrough and $11 Price Target
AtaiBeckley reported Phase 2b trial data for BPL-003 at the January 16 ACNP meeting showing significant, sustained antidepressant effects in treatment-resistant depression and secured FDA Breakthrough Therapy designation. Guggenheim initiated coverage with a Buy rating and $11 price target, while Cantor Fitzgerald reiterated an Overweight rating.
1. Phase 2b BPL-003 Trial Results
At the January 16 64th Annual ACNP meeting, AtaiBeckley presented Phase 2b data showing BPL-003 produced significant and sustained antidepressant effects in patients with treatment-resistant depression. The study reported both rapid onset and durability of response across key endpoints, underscoring its potential therapeutic impact.
2. FDA Designation and ACNP Recognition
Following the trial, BPL-003 received Breakthrough Therapy designation from the FDA, expediting its clinical development pathway. AtaiBeckley’s poster presentation was also selected as a Hot Topic at ACNP, highlighting the study’s competitive standing among neuropsychopharmacology research.
3. Analyst Coverage and Price Targets
On January 20, Guggenheim initiated coverage of AtaiBeckley with a Buy rating and an $11 price target, citing leadership in next-generation psychiatry. Earlier, Cantor Fitzgerald reiterated an Overweight rating, emphasizing BPL-003’s potential commercial viability in the psychedelic treatment landscape.